Alphamab (康宁杰瑞) IPO: Thoughts on Base-Line Valuation
Alphamab, a China-based biotech company, is seeking to raise USD 200 to 300 million via a listing on the Hong Kong Stock Exchange. In our previous...
697 Views
Alphamab IPO: Interims from Merck's Breast Cancer Trial Bodes Well for Alphamab and Junshi
Last night, Merck & Co Inc. (MRK US) announced that its Keytruda hits primary endpoint in Phase III (KEYNOTE-522) clinical trial in the...
681 Views
Alphamab (康宁杰瑞) IPO: Strong R&D Capability and Innovative Platforms
Alphamab, a China-based biotech company, is seeking to raise USD 200 to 300 million via a listing on the Hong Kong Stock Exchange. In this...
878 Views